BUZZ-OS Therapies rises after starting commercial production of cancer therapy

Reuters02-14

** Shares of drug developer OS Therapies OSTX.A rise 31.1% to $2.61 in morning trade

** Co says it is starting commercial production of its experimental therapy, OST-HER2 to treat a type of bone cancer called osteosarcoma

** OSTX says OST-HER2 has received "rare pediatric disease", "fast-track" and "orphan drug" designations from the U.S. FDA

** Co says it anticipates submitting an application for potential approval to the FDA for OST-HER2 in osteosarcoma in 2025

** OSTX adds if the therapy is approved, it would be eligible to receive a priority review voucher that it could then sell

** Stock fell 20.7% since its debut

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment